secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0001104659-24-036742
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio completes data cleaning for phase II/III Alzheimer's study; topline data expected April 2024
--------------------------------------------------------------------------------

- Data cleaning completed for phase II/III trial of buntanetap in mild to moderate Alzheimer's disease.
- Topline efficacy results expected in April 2024.
- Study enrolled 353 patients; 327 completed; three doses (7.5, 15, 30 mg) vs placebo over 12 weeks.
- All patients received standard of care in addition to buntanetap or placebo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924036742/0001104659-24-036742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924036742/tm249369d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-036742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer